
|Articles|September 1, 2016
ONCOLOGY Cartoon Caption Contest
Leave your caption idea in the comment section for the chance to have your caption featured in an upcoming issue of ONCOLOGY.
Advertisement
Leave your caption idea in the comment section for the chance to have your caption featured in an upcoming issue of ONCOLOGY.
Advertisement
Related Content
Advertisement


112 First-Line (1L) Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (mTNBC) for Whom Immunotherapy Was Not an Option: Primary Results From the Randomized, Phase 3 TROPION-Breast02 Trial
ByRebecca Dent, MD,Zhimin Shao,Peter Schmid, MD,Javier Cortés, MD,David W. Cescon,Shighira Saji,Kyung Hae Jung,Thomas Bachelot,Shouman Wang,Gul Basaran,Yee Soo Chae,Rofhiwa Mathiba,Shin-Cheh Chen,Agostina Stradella,Nicola Battelli,Naoki Niikura,Kechen Zhao,Petra Vukovic,Michah Maxwell,Tiffany Traina, MD, FASCO

TIP113 HERTHENA-PanTumor01 (NCT06172478): Expansion of a Global Phase 2 Trial of HER3-DXd in Patients With Advanced/Metastatic HR+/HER2− Breast Cancer
ByFunda Meric-Bernstam, MD,Christos Fountzilas,Izuma Nakayama,Takahiro Kogawa,Tomohiro Nishina,Thomas Powles, MBBS, MCRP, MD,Jin Won Kim,Yen-Yang Chen,Francois Ghiringhelli,Valentina Gambardella,James W. Smithy,Jérome Fayette,Fan Jin,Y.K. Chang,Kendall Sullivan,Sue Yueh,Ajlan Atasoy,Andrea Sporchia,Ragini Kudchadkar, MD,Hidetoshi Hayashi


Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD
2
How Might CAR T Cells and Bispecifics Evolve in Multiple Myeloma Therapy?
3
Perioperative Durvalumab Plus Enfortumab Vedotin Improves Survival in MIBC
4
Moving Bispecifics and Prophylaxis to Outpatient Multiple Myeloma Care
5


















































